Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Linkesch, W; Gisslinger, H; Ludwig, H; Flener, R; Sinzinger, H.
Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses
Acta Med Austriaca. 1985; 12(5):123-127
Web of Science
PubMed
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- 15 patients with myeloproliferative diseases and thrombocythaemia (7 Polycythaemia vera, 5 essential thrombocythaemia, 3 chronic myelogenous leukaemia) were assigned to a therapy with recombinant interferon (recombinant IFN-alpha-2C) in a prospective, controlled trial. Under therapy all patients showed a significant decrease in thrombocyte values. 51% of the patients revealed thrombocyte values within the normal range after 3 months of IFN therapy. Noted side effects of IFN therapy were dose-dependent and clinically well tolerated by the patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Clinical Trials -
- Drug Administration Schedule -
- Erythrocyte Count - drug effects
- Female - drug effects
- Humans - drug effects
- Interferon Type I - therapeutic use
- Leukemia, Myeloid - drug therapy
- Leukocyte Count - drug effects
- Male - drug effects
- Middle Aged - drug effects
- Myeloproliferative Disorders - drug therapy
- Platelet Count - drug effects
- Polycythemia Vera - drug therapy
- Prospective Studies - drug therapy
- Recombinant Proteins - therapeutic use
- Thrombocythemia, Hemorrhagic - drug therapy
- Thrombocytosis - drug therapy